New data and status updates for atopic dermatitis treatments in clinical trials will be presented at the American Academy of Dermatology annual meeting in San Diego this week. In this article, we offer some highlights.
Biologic Treatments for Moderate to Severe Atopic Dermatitis
A small study finds that the combination of methotrexate and azathioprine is safe and effective as maintenance treatment for patients with moderate-to-severe atopic dermatitis for up to five years.
Moisturizers were described as the “cornerstone of therapy” in atopic dermatitis in the 2014 AAD guidelines for topical therapies in atopic dermatitis, but the products differ greatly by ingredients which can improve the condition or make it worse.
Ocular comorbidity risk is already high in patients with atopic dermatitis and may increase even further as biologic agents are introduced, a study shows.
Thinking of psoriasis and atopic dermatitis as a spectrum, rather than separate diseases might lead to better understanding, and potentially better treatments.
Until recently, atopic dermatitis treatments were primarily limited to topical corticosteroids and systemic immunosuppressants.
Now, two new therapies have reached clinical practice. Nineteen more are in development.
Dupilumab given concomitantly with topical corticosteroids significantly improved signs and symptoms of atopic dermatitis (AD) in adults refractory to or intolerant of cyclosporine A, a study shows.
Early trial results show a significant reduction of itch with the oral NK-1 antagonist serlopitant
Dupilumab plus topical corticosteroids safe and effective after failure of cyclosporine in moderate-to-severe atopic dermatitis
There are two pathways that lead to atopic dermatitis. Their origins differ, but they both impair the immune system and skin barrier in AD.